Siegfried

expect more

Welcome to the Media + Analysts' Conference

Zurich, March 14, 2017

Important Notice

This document is solely for use in connection with the presentation held by Siegfried Holding AG. It is furnished to you solely for your information and you may not reproduce it or redistribute to any other person. The contents of this document are to be kept strictly confidential by you and may not be forwarded or disclosed to any other person.
No representation or warranty, express or implied, is made to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained herein. Siegfried Holding AG shall not have any liability whatsoever for any loss whatsoever arising from any use of this document, or its content, or otherwise arising in connection with this document.

This document may contain forward-looking statements which involve risks and uncertainties. These statements may be identified by such words as "may", "plans", "expects", "believes" and similar expressions, or by their context. These statements are made on the basis of current knowledge and assumptions. Various factors could cause actual future results, performance or events to differ materially from those described in these statements. No obligation is assumed to update any forward-looking statements.

Neither this document nor any copy of it may be taken or transmitted into the United States or distributed, directly or indirectly, in the United States or to any US person. In addition, neither this document nor any copy of it may be taken or transmitted into Canada or Australia or distributed or redistributed in Japan or to any resident thereof.
The distribution of this document in other jurisdictions may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions.

This document does not constitute or form part of an offer to sell or a solicitation of an offer to purchase any shares and neither it nor any part of it shall form the basis of, or be relied upon in connection with, any contract or commitment whatsoever.

By participating in the presentation or by accepting any copy of this document, you agree to be bound by the foregoing limitations.

1. Highlights
2. Facts & Figures
3. Status and Strategy
4. Outlook

Highlights

- Sharp increase in sales to CHF 717.7 million, 49.3% increase in CHF (+47.3% in LC)
- EBITDA CHF 104.2 million (+30.1%) before and 96.7 million after integration costs
- Net profit of CHF 27.9 million below prior year due to integration costs, higher financing costs and tax expense vs. tax benefits in former years
- Post merger integration process of BASF's CMO-/API-business including 3 sites completed
- New plant in Zofingen put into operation
- The Nantong facility received approval for large-scale production. First commercial batches delivered
- Outlook
  - High single-digit sales growth
  - EBITDA double-digit growth

1. Highlights
2. **Facts & Figures**
3. Status and Strategy
4. Outlook

Net sales

CHF million	2016	2015	Change CHF (LC)
Drug Substances	557.9	333.2	+67.5% (+65.4%)
Drug Products	159.8	147.4	+8.4% (+6.3%)
Total	**717.7**	**480.6**	**+49.3% (+47.3%)**

Comments

- Organic sales growth with 6.7% above market
- Drug Substance growth driven by acquisition effect of former BASF business.
- Drug Products: strong growth of sterile business.



Significant increase in operating profits



- Non-recurring integration costs were CHF 7.5m on EBITDA and EBIT level (2015 CHF 3.0m)
- This leads to the reported EBITDA of CHF 96.7m
- Higher tax expense and financing costs led to only slight reduction in net profit.

Dilution of operating margins due to acquisition



- Dilutive effect from acquisition on operating margins (BASF API and supply business)
- Negative impact on net profit margin due to higher financial expenses and termination of capitalization of tax losses (NOLs)
- Target range of 15 – 20% EBITDA margin to be achieved from 2018 on

P&L

CHF million	2016	2015
Net sales	**717 729**	**480 571**
Cost of goods sold	– 608 509	– 389 919
Gross profit	**109 220**	**90 652**
Marketing and sales costs	– 16 028	– 13 041
Research and development costs	– 21 193**	– 23 289
Admin and general overhead costs	– 31 488	– 23 311
Other operating income	6 239	12 423
Share of result of associates	– 36	– 33
Operating profit (EBIT)	**46 714** *	**43 401**
Financial Result	– 11 981	– 6 350
Tax result	– 6 827	2 049
Net profit	**27 906**	**39 100**

EPS	7.18	9.89
EPS diluted	7.04	9.76

- Increase in General Admin due to integration costs (TSA with BASF)
- Positive tax result 2015 due to capitalization of tax losses

* EBIT before integration costs CHF 54.2 million **after substraction of R&D expenses allocated to sold products

Significant improvement of operating cash flow

CHF million	2016	2015
Operating Cashflow before changes in NWC	95 907	65 025
Change in NWC	–38 794	–41 950
Operating Cashflow	**57 113**	**23 075**
Purchase of PPE and intangibles (net)	– 68 287	– 89 370
Acquisitions	2 157	– 160 361
Other investing activities	368	– 3 105
Cashflow for investing activities	**– 65 762**	**– 252 836**
Cashflow from financing activities	**7 895**	**238 173**
Treasury shares	**–13 242**	**–14 195**
Net change in cash	**– 13 996**	**– 5 783**

- Significant increase in operating cash flow before and after changes in NWC. Increase in NWC driven by high sales in Q4 2016 and high A/R position at year-end; on the other hand reduction of inventories.
- Reduction of PPE compared to 2015; PPE according investment plan. Still mainly driven by Nantong and new production building in Zofingen.
- Placing of second public hybrid in October 2016 in the amount of CHF 160m to repay bank debt; increase in own shares to cover conversion of RAG Convertible Hybrid Bond.
- Net Debt/EBITDA ratio 0.6 and Equity Ratio 65% end of December 2016.

Pay-out – proposal to the AGM on April 20, 2017

- The Board of Directors proposes a pay-out
  from the capital contribution reserves of CHF 2.00 per share (2016: CHF 1.80 per share) to the AGM on April 20, 2017 (in total appr. CHF 8.0m).
- Pay-out from capital contribution reserve, tax free.
- Remaining capital contribution reserve of CHF 92.5 for future tax free pay-outs.

1. Highlights
2. Facts & Figures
3. Status and Strategy
4. Outlook

Siegfried`s new production network offers an unique combination of flexibility and integration on a global base

DS: Drug Substances (API)
DP: Drug Products

New offers at record level



*For 5 years (2017-2021).


= after risk adjustment

Siegfried's EVOLVE strategy for 2016–2020: Siegfried will further enhance its pure-play CDMO business model

Fields of action

Growth

- **Strengthen offerings:**
  - Expand global solida drug product footprint
  - Expand overall presence with own production facilities (e.g. US)
  - Enhance development setup
- **Grow within value chain of existing business:**
  - Reach critical size in drug product sector
  - Backward integration
- **Diversify into adjacent new business**
  - Enhance technology base (micronization, lyophilization, spray drying, additional high-potent manufacturing capabilities)

1. Highlights HY 2016
2. Facts & Figures
3. Status and Strategy
4. Outlook

Outlook

The Siegfried Group expects

- high single-digit sales growth
- Double-digit growth of EBITDA
- improved EBITDA margin

Siegfried

expect more

Thank you for your attention